Company Profile

Ulisse BioMed S.p.A. is a biotechnology company specialized in developing medical diagnostics, theranostics and therapeutics solutions. The company has 3 technology platforms, namely, Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics).
Italy accounts for all net sales.


Source: Cofisem - Last Update: 2024-06-19

Key Executives
Chief Executive Officer Nicola Basile
Chief Investor Relations Officer Nicola Basile


Source: Cofisem - Last Update: 2024-06-19

Key Figures
Millenium 2023 2022 2021 2020 2019
Net sales 66 138 277 429 11
Consumed purchases 316 328 117 141 116
Labour costs 497 330 141 111 524
Operating profit -4,796 -1,306 -604 224 -1,116
Income tax 0 0 0 2 -18
Net income -4,796 -1,308 -604 222 -1,098
Net income (Group share) -4,797 -1,308 -604 222 -1,098
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards Local GAAP Local GAAP Local GAAP Local GAAP Local GAAP

Source: Cofisem - Last Update: 2024-06-19

Shareholder information
Alberto Amati 12.39 %
Lorenzo Colombo 3.85 %
Stefano Lo Priore 16.43 %
Bruna Marini 1.05 %
Matteo Petti 0.65 %
Other shareholders 24.33 %
Copernico Innovazione S.r.l. 3.93 %
Free float 30.19 %
Good Harvest Ventures 7.18 %


Source: Cofisem - Last Update: 2024-06-19

Please contact MyQuestion.Italy@euronext.com for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Ulisse Biomed


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.